Skip to content
TrialScanner

NCT04245722

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1TerminatedFATELead

Registry record

Lead sponsor
Fate Therapeutics
Conditions
Lymphoma, B-Cell; Chronic Lymphocytic Leukemia
Primary completion
Sep 27, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04245722 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04245722: FT596 as a Monotherapy and... | TrialScanner